AmyriAD Therapeutics B.V., a clinical-stage biopharmaceutical company focused on cognition in central nervous system disorders, announced the acquisition of Recognify Life Sciences, Inc. and its lead clinical-stage program, RL-007 (inidascamine). The acquisition expands AmyriAD's cognition pipeline while preserving Ismidenon (AD-101) as the company's lead Alzheimer's disease program.
The acquisition strengthens AmyriAD's clinical-stage cognition pipeline while preserving Ismidenon as the company's lead Alzheimer's disease program.
"AmyriAD's singular focus on cognition and its experienced CNS team make it the right owner to take inidascamine forward. As shareholders, we look forward to participating in the program's next chapter," said Matthew P. Pando, Ph.D., President & CEO of Recognify Life Sciences.